R&D

Pioneering Neuronal Health

We’re building a TCAP platform to address many neuropsychiatric disorders and other neurodegenerative diseases that are impacted by the stress response system of the brain.

We’ve spent the last several years building a robust preclinical pharmacology package for PT00114, and have completed all IND enabling studies to enter the clinic in Q1 2022.

We will be conducting our first clinical study in collaboration with Harvard/MGH and Dr. Maurizio Fava, a world-renowned psychiatrist and major voice in the effort to find new, effective treatments for patients with depression, anxiety, PTSD, and other stress-related diseases.

TCAP-1 phases

© 2021 Protagenic Therapeutics, Inc.